Clinical trials: Dermatitis Atopic
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Atopic Dermatitis
LEO 29102 Single and Multiple Dose Study by Dermal Application
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects.
- Trial name
- NCT00891709
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
- Trial name
- NCT03826901
- Testing
- delgocitinib
- Where
- 16 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- LEO Pharma
Dermatitis, Atopic, Rosacea
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
The purpose of this study is to evaluate the efficacy and tolerance of a gentle facial cleanser in participants with sensitive skin (eczema/atopic dermatitis, rosacea, acne, cosmetic intolerance syndrome).
- Conditions
- Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
- Trial name
- NCT05094700
- Testing
- Non-marketed Cosmetic Facial Cleanser
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis
Atopic dermatitis is one of the most common skin diseases, with a lifetime prevalence of up to 20%, and an increasing number of cases.
- Trial name
- NCT00583895
- Testing
- 10% ImCOOH cream
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Valletta Health B.V.
Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis…
- Trial name
- NCT07465120
- Testing
- CMS-D001 50mg, CMS-D001 100mg, CMS-D001 200mg
- Where
- 28 sites in China
- Volunteers
- 160 people
- Sponsor
- Dermavon Holdings Limited
Moderate-to-severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
The primary objective of this study is to investigate the efficacy of nemolizumab administered in combination with topical background therapy (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]) in…
- Trial name
- NCT05056779
- Testing
- Nemolizumab
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Objective of this study is to further assess the response to treatment and safety of 0.03% tacrolimus (FK506) ointment when used for 6 months in pediatric patients with moderate to severe atopic dermatitis, known to be responsive…
- Trial name
- NCT00691262
- Testing
- tacrolimus ointment
- Where
- 9 sites in Italy
- Volunteers
- 166 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Probiotic on Atopic Dermatitis in Infant
The clinical trial will be carried out in China Medical University Hospital. The overall plan is a double-blind trial. All recruited 3 months-3 years old atopic dermatitis (AD) patients are divided into two groups, 50 in each…
- Trial name
- NCT05286047
- Testing
- Bifidobacterium longum CCFM1029
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Glac Biotech Co., Ltd
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 2 (NCT03160885)
- Testing
- Tralokinumab
- Where
- 115 sites in United States, Australia and 7 more
- Volunteers
- 794 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04936113
- Testing
- FB-401
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forte Biosciences, Inc.
Atopic Dermatitis
Topical Application of AS101 for the Treatment of Atopic Dermatitis
Atopic Dermatitis is a chronic non contagious disease that causes itchy, inflamed skin. The purpose of this study is to evaluate the safety and efficacy of topical AS101 ointment for the treatment of Atopic dermatitis.
- Trial name
- NCT00927212
- Testing
- AS101 ointment
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- BioMAS Ltd
Dermatitis, Atopic
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03059693
- Testing
- HAT1 topical cream, Vehicle cream
- Volunteers
- 48 people
- Sponsor
- Haus Bioceuticals
Atopic Dermatitis
To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children
The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in…
- Trial name
- NCT00886587
- Testing
- F# 11054-010, F# 10495-053
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Atopic Dermatitis
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3033 in subjects with moderate-to-severe atopic dermatitis…
- Trial name
- NCT07549984
- Testing
- IBI3033
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Children and Adolescents With Moderate-to-severe Atopic Dermatitis
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06713499
- Testing
- SHR-1819 injection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD1 (NCT03334396)
- Testing
- Baricitinib
- Where
- 93 sites in Czechia, Denmark and 8 more
- Volunteers
- 660 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.